Aceragen | IDRA - Aktuelle Verpflichtungen



Aktuelle Verpflichtungen Veränderung Datum
Abbott USD 16.15B 1.66B 2026-09
Agenus USD 231.82M 17.42M 2026-06
Alnylam Pharmaceuticals USD 2.06B 550.49M 2026-09
Alterity Therapeutics Limited AUD 1.73M 2.77M 2025-12
Amgen USD 23.23B 2.27B 2026-09
Biogen USD 3.9B 18.7M 2026-09
BioMarin Pharmaceutical USD 1.6B 59.17M 2026-09
Cipla INR 69.77B 366.6M 2026-09
Clal Biotechnology ILS 6.66M 3.75M 2023-12
Compugen USD 22.63M 596K 2026-06
CSL USD 4.61B 207M 2025-12
Eli Lilly USD 47B 745M 2026-09
Gilead Sciences USD 12B 982M 2026-09
GlaxoSmithKline GBP 20.72B 814M 2026-09
Grifols EUR 2.37B 156.97M 2025-12
Merck USD 28.8B 1.07B 2026-09
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Pfizer USD 31.73B 920M 2026-09
Roche Holding CHF 28.85B 846M 2026-06
Sarepta Therapeutics USD 656.35M 153.44M 2026-09
Ultragenyx Pharmaceutical USD 389M 38M 2026-09
X T L Biopharmaceuticals USD 420K 341K 2025-12